| Nanoparticle albumin-bound paclitaxel: a novel Cremphor-EL-free formulation of paclitaxel. | |
| | |
MedLine Citation:
|
PMID: 17716129 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Standard formulation paclitaxel requires the use of solvents, such as Cremphor-EL, which contribute to some of the toxicities commonly associated with paclitaxel-based therapy. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free formulation of paclitaxel. The formulation is prepared by high-pressure homogenization of paclitaxel in the presence of serum albumin into a nanoparticle colloidal suspension. The human albumin-stabilized paclitaxel particles have an average size of 130 nm. Nab-paclitaxel has several practical advantages over Cremphor-EL-paclitaxel, including a shorter infusion time (30 min) and no need for premedications for hypersensitivity reactions. The nab-paclitaxel formulation eliminates the impact of Cremphor-EL on paclitaxel pharmacokinetics and utilizes the endogenous albumin transport mechanisms to concentrate nab-paclitaxel within the tumor. A recent Phase III trial compared nab- and Cremphor-EL-paclitaxel in patients with metastatic breast cancer. Patients treated with nab-paclitaxel experienced a higher response, longer time to tumor progression and, in patients receiving second-line or greater therapy, a longer median survival. Patients treated with nab-paclitaxel had a significantly lower rate of severe neutropenia and a higher rate of sensory neuropathy. The preclinical and clinical data indicate that the nab-paclitaxel formulation has significant advantages over Cremphor-EL-paclitaxel. |
| | |
Authors:
|
Thomas E Stinchcombe |
Related Documents
:
|
7349619 - Lithium and mood change in affective disorder patients. 16601939 - Non-convulsive status epilepticus during lithium treatment at therapeutic doses. 11576009 - Assessing diagnostic accuracy and tympanocentesis skills in the management of otitis me... 2738909 - The subclass profile and complement activating potential of anti-alpha-gliadin antibodi... 20712749 - Lamotrigine versus lithium as maintenance treatment in bipolar i disorder: an open, ran... 6423259 - The long-term effect of lithium carbonate on tardive dyskinesia. 21205379 - The italian version of the zarit burden interview: a validation study. 3381929 - Graphic representation of the life course of illness in patients with affective disorder. 17067659 - Treatment of proliferative lupus nephritis--a critical approach. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Nanomedicine (London, England) Volume: 2 ISSN: 1748-6963 ISO Abbreviation: Nanomedicine (Lond) Publication Date: 2007 Aug |
Date Detail:
|
Created Date: 2007-08-24 Completed Date: 2007-09-18 Revised Date: 2010-01-28 |
Medline Journal Info:
|
Nlm Unique ID: 101278111 Medline TA: Nanomedicine (Lond) Country: England |
Other Details:
|
Languages: eng Pagination: 415-23 Citation Subset: IM |
Affiliation:
|
University of North Carolina at Chapel Hill, Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599-7305, USA. thomas_stinchcombe@med.unc.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Albumins
/
chemistry* Antineoplastic Agents / administration & dosage, chemistry Clinical Trials as Topic / trends* Drug Carriers / chemistry* Drug Compounding / methods Humans Nanoparticles / chemistry*, therapeutic use Neoplasms / drug therapy* Paclitaxel / administration & dosage*, chemistry* Particle Size Solvents / chemistry |
| Chemical | |
Reg. No./Substance:
|
0/Albumins; 0/Antineoplastic Agents; 0/Drug Carriers; 0/Solvents; 33069-62-4/Paclitaxel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nanotechnology: the next wave of commercial development for health and medical devices--an Australia...
Next Document: Rise of the nanomachine: the evolution of a revolution in medicine.